Barclays PLC Grows Holdings in The Chemours Company (NYSE:CC)

Barclays PLC raised its position in The Chemours Company (NYSE:CC) by 28.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,549 shares of the specialty chemicals company’s stock after buying an additional 23,766 shares during the period. Barclays PLC’s holdings in Chemours were worth $2,185,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vision One Management Partners LP purchased a new position in Chemours in the third quarter valued at about $28,252,000. Two Sigma Advisers LP raised its position in shares of Chemours by 9.4% in the 3rd quarter. Two Sigma Advisers LP now owns 503,100 shares of the specialty chemicals company’s stock valued at $10,223,000 after purchasing an additional 43,200 shares in the last quarter. RBF Capital LLC boosted its stake in shares of Chemours by 42.8% during the 3rd quarter. RBF Capital LLC now owns 414,618 shares of the specialty chemicals company’s stock valued at $8,425,000 after buying an additional 124,311 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Chemours during the third quarter worth approximately $2,449,000. Finally, HighTower Advisors LLC increased its stake in shares of Chemours by 10.1% in the third quarter. HighTower Advisors LLC now owns 15,020 shares of the specialty chemicals company’s stock worth $300,000 after buying an additional 1,384 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours Price Performance

Shares of Chemours stock opened at $17.54 on Thursday. The Chemours Company has a 1 year low of $15.10 and a 1 year high of $32.70. The company has a market cap of $2.62 billion, a P/E ratio of 35.08 and a beta of 1.80. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The stock has a 50-day moving average price of $19.59 and a 200 day moving average price of $20.43.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year. As a group, analysts expect that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.70%. The ex-dividend date was Friday, November 15th. Chemours’s dividend payout ratio is currently 200.00%.

Wall Street Analyst Weigh In

CC has been the topic of a number of recent research reports. Morgan Stanley reduced their price target on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 5th. Barclays boosted their price objective on Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group dropped their price target on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $25.00 target price on shares of Chemours in a research note on Thursday, December 12th. Finally, BMO Capital Markets increased their price objective on Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $24.88.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now owns 16,645 shares of the company’s stock, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.47% of the stock is currently owned by company insiders.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.